ATE388230T1 - Neisseria meningitidis antigene und zusammenstellungen - Google Patents

Neisseria meningitidis antigene und zusammenstellungen

Info

Publication number
ATE388230T1
ATE388230T1 AT99922752T AT99922752T ATE388230T1 AT E388230 T1 ATE388230 T1 AT E388230T1 AT 99922752 T AT99922752 T AT 99922752T AT 99922752 T AT99922752 T AT 99922752T AT E388230 T1 ATE388230 T1 AT E388230T1
Authority
AT
Austria
Prior art keywords
neisseria meningitidis
compositions
meningitidis antigens
antigens
proteins
Prior art date
Application number
AT99922752T
Other languages
English (en)
Inventor
Claire Fraser
Cesira Galeotti
Guido Grandi
Erin Hickey
Vega Masignani
Mariarosa Mora
Jeremy Petersen
Mariagratia Pizza
Rino Rappuoli
Giulio Ratti
Enzo Scalato
Maria Scarselli
Herve Tettelin
J Venter
Original Assignee
Novartis Vaccines & Diagnostic
Inst Genomic Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27574612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE388230(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic, Inst Genomic Research filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE388230T1 publication Critical patent/ATE388230T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
AT99922752T 1998-05-01 1999-04-30 Neisseria meningitidis antigene und zusammenstellungen ATE388230T1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US8375898P 1998-05-01 1998-05-01
US9486998P 1998-07-31 1998-07-31
US9906298P 1998-09-02 1998-09-02
US9899498P 1998-09-02 1998-09-02
US10374998P 1998-10-09 1998-10-09
US10379698P 1998-10-09 1998-10-09
US10379498P 1998-10-09 1998-10-09
US12152899P 1999-02-25 1999-02-25

Publications (1)

Publication Number Publication Date
ATE388230T1 true ATE388230T1 (de) 2008-03-15

Family

ID=27574612

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05077865T ATE376591T1 (de) 1998-05-01 1999-04-30 Neisseria meningitidis antigene und zusammenstellungen
AT99922752T ATE388230T1 (de) 1998-05-01 1999-04-30 Neisseria meningitidis antigene und zusammenstellungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05077865T ATE376591T1 (de) 1998-05-01 1999-04-30 Neisseria meningitidis antigene und zusammenstellungen

Country Status (17)

Country Link
US (9) US7576176B1 (de)
EP (23) EP2261343A3 (de)
JP (9) JP5102414B2 (de)
CN (3) CN101293920B (de)
AT (2) ATE376591T1 (de)
AU (1) AU761780B2 (de)
BR (1) BR9910089A (de)
CA (2) CA2330838C (de)
CY (2) CY1109649T1 (de)
DE (2) DE69938302T2 (de)
DK (2) DK1645631T3 (de)
ES (3) ES2294629T3 (de)
HK (1) HK1090382A1 (de)
MX (4) MX343752B (de)
NZ (4) NZ532665A (de)
PT (3) PT1645631E (de)
WO (1) WO1999057280A2 (de)

Families Citing this family (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE355375T1 (de) 1996-01-04 2006-03-15 Novartis Vaccines & Diagnostic Bakterioferritin aus helicobacter pylori
JP2001500738A (ja) 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
CA2308606A1 (en) * 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
EP2261343A3 (de) * 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
US6756493B1 (en) 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US6693186B2 (en) 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
US6610306B2 (en) 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
EP1137777B1 (de) * 1998-12-08 2011-10-05 GlaxoSmithKline Biologicals s.a. Neue verbindungen abgeleitet von neisseria meningitidis
WO2000042193A1 (en) * 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigen
WO2000042192A1 (en) * 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis polypeptide basb052
CA2360658A1 (en) * 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
AU2109700A (en) 1999-01-22 2000-08-07 Smithkline Beecham Biologicals (Sa) Novel compounds
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
GB9902937D0 (en) * 1999-02-10 1999-03-31 Smithkline Beecham Biolog Novel compounds
PT1154790E (pt) * 1999-02-26 2005-03-31 Chiron Srl Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
DE60043499D1 (de) * 1999-03-12 2010-01-21 Glaxosmithkline Biolog Sa Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
AU2004240199B2 (en) * 1999-04-30 2007-05-17 Novartis Vaccines And Diagnostics S.R.L. Conserved Neisserial antigens
PT1228217E (pt) 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Antígenos de neisseria conservados
CA2929348A1 (en) * 1999-05-19 2000-11-30 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
AU2013200678B2 (en) * 1999-05-19 2014-08-21 Glaxosmithkline Biologicals S.A. Combination Neisserial compositions
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
AU2013203304B2 (en) * 1999-05-19 2014-10-09 Glaxosmithkline Biologicals S.A. Combination Neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
AU2003271337B2 (en) * 1999-08-03 2005-07-21 Smithkline Beecham Biologicals S.A. Vaccine composition
ES2564463T3 (es) 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Péptidos antigénicos de Neisseriales
RU2002117308A (ru) 1999-11-29 2004-03-10 Чирон Спа (It) 85 кДа АНТИГЕН NEISSERIA
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
BRPI0107679B8 (pt) 2000-01-17 2021-05-25 Chiron Spa composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma
ES2389719T3 (es) 2000-01-25 2012-10-30 The University Of Queensland Proteínas que comprenden regiones conservadas del antígeno de superficie de Neisseria meningitidis NhhA
CN100339482C (zh) 2000-02-28 2007-09-26 启龙股份公司 奈瑟球菌蛋白质的杂交表达
AU2001280883A1 (en) 2000-07-27 2002-02-13 The Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
US7261901B2 (en) 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
WO2002060936A2 (en) * 2001-01-31 2002-08-08 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
ATE455793T1 (de) * 2001-04-17 2010-02-15 Novartis Vaccines & Diagnostic Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
DE60236864D1 (de) 2001-05-31 2010-08-12 Novartis Vaccines & Diagnostic Chimere alphavirus-replikon-partikel
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
BR0211494A (pt) 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
AU2012202488B2 (en) * 2001-09-06 2014-01-16 Glaxosmithkline Biologicals S.A. Hybrid and tandem expression of Neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
BR0213119A (pt) * 2001-10-03 2004-12-28 Chiron Corp Composição imunogênica e uso da mesma
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
NZ562929A (en) 2001-12-12 2009-07-31 Novartis Vaccines & Diagnostic Immunisation against chlamydia trachomatis
JP4646516B2 (ja) 2002-02-20 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着したポリペプチド含有分子を有する微粒子
NZ574530A (en) 2002-08-02 2010-12-24 Glaxosmithkline Biolog Sa Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB-neisseria minigitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2351579B1 (de) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Poylpeptidimpfstoffe zum breiten Schutz gegen hypervirulente Meningo-kokken-Linien
SI1556477T1 (sl) 2002-11-01 2017-12-29 Glaxosmithkline Biologicals S.A. Sušilni postopek
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
EP2279746B1 (de) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
EP2263687B1 (de) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogene zusammensetzungen enthaltend phospholipid
ATE552844T1 (de) 2003-01-30 2012-04-15 Novartis Ag Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
EP2258365B1 (de) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Verwendung von organischen verbindungen zur immunstärkung
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20070253964A1 (en) * 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
JP4522997B2 (ja) 2003-08-13 2010-08-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｔｆｐｉおよびｔｆｐｉアナログを精製するための改良された方法
BR122017002991B1 (pt) 2003-10-02 2023-01-10 Novartis Vaccines And Diagnostics S.R.L. Composições imunogênicas aquosas para múltiplos sorogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23236A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
CU23237A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
ATE395356T1 (de) * 2004-06-29 2008-05-15 Ct For Disease Control Dept Of Oberflächenprotein aus neisserien
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419918D0 (en) * 2004-09-08 2004-10-13 Imp College Innovations Ltd Vaccine
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
DK1858920T3 (en) 2005-02-18 2016-02-29 Glaxosmithkline Biolog Sa PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI
ATE552267T1 (de) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic Immungene von uropathogenen escherichia coli
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
EP1723964A1 (de) * 2005-05-20 2006-11-22 Institut Pasteur Verwendung von Penicillin-bindenden Proteinen, Polynukleotiden oder dagegen gerichteten Antikörpern zur Vorbeugung oder Behandlung von bakteriellen Infektionen
EP2357000A1 (de) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische Immunisierungen mit Alphavirus-Replikonpartikeln
EP1969001A2 (de) 2005-11-22 2008-09-17 Novartis Vaccines and Diagnostics, Inc. Norovirus- und sapovirus-antigene
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US20110008279A1 (en) * 2005-12-06 2011-01-13 Vega Masignani Methods and Compositions Relating to Adhesins as Adjuvants
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
EP2357184B1 (de) 2006-03-23 2015-02-25 Novartis AG Imidazochinoxalinverbindungen als Immunmodulatoren
CU23572A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2032161B1 (de) 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los impfstoffe
MX2008016280A (es) 2006-06-29 2009-03-26 Novartis Ag Polipeptidos a partir de neisseria meningitidis.
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
JP5653215B2 (ja) 2007-09-12 2015-01-14 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
CN101951949B (zh) 2007-10-19 2013-10-02 诺华股份有限公司 脑膜炎球菌疫苗制剂
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8426163B2 (en) 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
WO2009076158A1 (en) 2007-12-07 2009-06-18 Novartis Ag Compositions for inducing immune responses
US7833776B2 (en) * 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
BRPI0821240B8 (pt) 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
EP2886551A3 (de) 2008-02-21 2015-09-23 Novartis AG Meningokokken-FHBP-Polypeptide
CA2716706C (en) 2008-03-03 2014-02-18 Irm Llc Compounds and compositions as tlr activity modulators
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
WO2009143168A2 (en) * 2008-05-19 2009-11-26 Novartis Ag Vaccine assays
WO2009150531A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
GB0810742D0 (en) * 2008-06-12 2008-07-16 Univ Nottingham Enzyme
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
PT2349520T (pt) 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Método de purificação para hidrato de carbono de estreptococos grupo a
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
NZ593674A (en) 2008-12-17 2013-03-28 Novartis Ag Meningococcal vaccines including hemoglobin receptor
BRPI1005670A8 (pt) 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
JP5668049B2 (ja) 2009-03-24 2015-02-12 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
BRPI1013902A2 (pt) 2009-04-30 2019-09-24 Children´S Hospital & Res Center At Oakland proteínas de ligação de fator quimérico h(fhbp) é método de uso
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
CN102762226A (zh) 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
EP2443250B8 (de) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA Komplement-vermittelte antikörper-abhängige und opsonische bakterienassays mit hohem durchlauf
TWI409275B (zh) 2009-06-22 2013-09-21 Nat Health Research Institutes 脂質化腫瘤相關抗原及其免疫治療的組成物及方法
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
BR112012004276A2 (pt) 2009-08-27 2017-10-24 Novartis Ag adjuvante compreendendo alumínio, oligonucleotídeo e policátion
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
MX2012004850A (es) 2009-10-27 2012-05-22 Novartis Ag Polipeptidos fhbp meningococicos modificados.
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
EP2512478B1 (de) 2009-12-15 2017-04-19 GlaxoSmithKline Biologicals SA Homogene suspension aus immunstimulierenden verbindungen und ihre verwendung
CA2792691A1 (en) * 2010-03-11 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition or vaccine against gram-negative bacterial, for example, neisserial, infection or disease
CA2793510A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
WO2011119759A1 (en) 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
WO2011127360A1 (en) 2010-04-08 2011-10-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
CN103189071A (zh) 2010-08-23 2013-07-03 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
GB201014967D0 (en) * 2010-09-09 2010-10-20 Univ Southampton Composition
US20120070457A1 (en) * 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP2613805B1 (de) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Nada und/oder nhba überexprimierende meningococcus und davon abgeleiteten aussenmembranvesikeln
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
PL2491788T3 (pl) 2011-02-25 2016-07-29 Kraft Foods R & D Inc Wyrób spożywczy z formowanym korpusem
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
JP6499446B2 (ja) 2011-06-24 2019-04-10 エピットジェネシス・インコーポレーテッド 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
WO2013033398A1 (en) 2011-08-31 2013-03-07 Children' S Hospital & Research Center Oakland Engineered sequences to facilitate expression of antigens in neisseria and methods of use
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
AU2013229063B2 (en) 2012-03-09 2016-10-06 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RU2644340C2 (ru) 2012-06-14 2018-02-08 Новартис Аг Вакцины для менингококка серогруппы х
WO2014016152A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
EP2903638B1 (de) 2012-10-03 2019-12-18 GlaxoSmithKline Biologicals SA Immunogene zusammensetzung
AU2013344571A1 (en) 2012-11-16 2015-06-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Gonorrheal MtrE peptides and vaccines
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
AU2014296027A1 (en) 2013-08-02 2016-02-04 Children's Hospital & Research Center At Oakland Non-naturally occurring factor H binding proteins (fHbp) and methods of use thereof
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
NZ766005A (en) 2014-07-23 2024-03-22 Children’S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
EP3298031B1 (de) * 2015-05-18 2020-10-21 BiOMVis Srl Immunogene zusammensetzungen enthaltend bakterielle aussenmembranvesikel und ihre verwendung
US10962534B2 (en) 2016-02-22 2021-03-30 Boehringer Ingelheim Vetmedica Gmbh Method for the immobilization of biomolecules
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
EP3263695A1 (de) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogene zusammensetzungen
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112020001255A2 (pt) 2017-07-21 2020-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services composições imunogênicas de neisseria meningitidis
WO2019126197A1 (en) 2017-12-18 2019-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacterial polysaccharide-conjugated carrier proteins and use thereof
CN111867623A (zh) 2018-02-12 2020-10-30 英尼穆内公司 Toll样受体配体
CN108950056B (zh) * 2018-08-30 2021-08-20 安徽农业大学 与小麦种子休眠/穗发芽抗性相关的caps标记及其检测方法
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
GB2583070B (en) 2019-03-20 2023-09-13 Schlumberger Technology Bv Viscosification of aqueous solutions
WO2020188343A1 (en) * 2019-03-21 2020-09-24 Fonterra Co-Operative Group Limited Compositions comprising polar lipids for maintaining or increasing mobility and vitality
WO2021022001A1 (en) * 2019-08-01 2021-02-04 Trustees Of Tufts College Vaccine compositions and methods of selecting antigens
US11865981B2 (en) * 2020-05-05 2024-01-09 Thor Tech, Inc. Wire loom support
KR20230117105A (ko) 2020-11-04 2023-08-07 엘리고 바이오사이언스 큐티박테리움 아크네스 재조합 파지, 그의 제조 방법 및 용도
CN113773366B (zh) * 2021-07-27 2023-06-16 四川丽妍工坊生物科技有限公司 一种抗炎多肽bmp14及其制备方法和应用
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2386796A (en) 1942-08-05 1945-10-16 Bond Crown & Cork Co Extruding device
DE2855719A1 (de) 1978-12-22 1980-07-10 Siemens Ag Zahnaerztliche handstueckanordnung
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
DK188582A (da) 1981-04-29 1982-10-30 Biogen Nv Bacillus-kloningsvektorer rekombinations-dna-molekyler bacillus-vaerter transformeret dermed samt fremgangsmaader til ekspressionaf fremmede dna-sekvenser og fremstilling af polypeptideer som er kodede dermed
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341116C (en) 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
DE3485810T2 (de) 1983-05-27 1992-12-10 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (de) 1983-10-03 1986-12-30 Genentech, Inc. Xenogeneisches Expressionskontrollsystem, Verfahren zu dessen Verwendung, dieses enthaltende Expressionsvektoren, mit denselben transformierte Zellen und daraus hergestellte heterolose Proteine
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
ATE102250T1 (de) 1984-05-11 1994-03-15 Chiron Corp Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
EP0196056B1 (de) 1985-03-28 1991-05-22 Chiron Corporation Expression durch Verwendung von Fusionsgenen für Proteinproduktion
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
ES2061482T3 (es) 1986-05-02 1994-12-16 Gist Brocades Nv Metodo para la identificacion de secuencias de señal secretora para sintesis de proteina extracelular en bacillus.
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
ATE247708T1 (de) 1986-10-02 2003-09-15 Massachusetts Inst Technology Verfahren zur regulierung der metabolischen stabilität von proteinen
EP0273116A3 (de) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonokokken- und Meningokokken-Polypeptide, Impfstoffe und Diagnostiken
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE3888561T2 (de) 1987-03-23 1994-09-01 Zymogenetics Inc Hohe Proteinsyntheserate in Hefe.
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
EP0378576B1 (de) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduktionsveränderte fibroblasten und ihre anwendung
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
CN1049686C (zh) 1987-11-18 2000-02-23 希龙股份有限公司 非ａ和非ｂ肝炎病毒的诊断及疫苗
JPH01144977A (ja) * 1987-11-30 1989-06-07 Agency Of Ind Science & Technol 新規組換えプラスミドｐＴＰＧＩＦ２
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4973551A (en) 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
CH684094A5 (de) 1988-03-21 1994-07-15 Viagene Inc Rekombinante Retroviren.
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
NL8803111A (nl) 1988-12-19 1990-07-16 Nederlanden Staat Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
ES2070312T5 (es) 1988-12-19 2003-05-16 American Cyanamid Co Vacuna de proteina de membrana exterior meningococica de clase 1.
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
EP0454781B1 (de) 1989-01-23 1998-12-16 Chiron Corporation Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
JPH04503306A (ja) 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション 単純ヘルペスウイルス１型発現ベクター
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
EP0463056A1 (de) 1989-03-17 1992-01-02 E.I. Du Pont De Nemours And Company Externe regulierung der genexpression
EP0737750B1 (de) 1989-03-21 2003-05-14 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ES2080153T3 (es) 1989-08-15 1996-02-01 Pasminco Australia Ltd Absorcion del vapor de cinc en el plomo fundido.
CA2066053C (en) 1989-08-18 2001-12-11 Harry E. Gruber Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
PL169801B1 (pl) 1990-07-27 1996-08-30 Chiron Corp sposób wykonania próby hybrydyzacji kwasu nukleinowego PL
DK0546118T3 (da) * 1990-08-23 2004-02-16 Univ North Carolina Transferrinbindende proteiner fra Neisseria gonorrhoeae og Neisseria meningtidis
CA2092195C (en) 1990-09-21 2000-04-18 Douglas J. Jolly Retroviral packaging cell line
WO1992007945A1 (en) 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
DE69132031T2 (de) 1990-12-20 2000-07-13 Arch Dev Corp Kontrolle der genexpression durch ionisierende strahlung
WO1992013871A1 (en) * 1991-01-31 1992-08-20 Washington University Polypeptides and polynucleotides useful for the diagnosis and treatment of pathogenic neisseria
ES2127217T3 (es) 1991-03-14 1999-04-16 Imclone Systems Inc Epitopos de porina hibridos de recombinacion.
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH0515375A (ja) * 1991-07-11 1993-01-26 Kanegafuchi Chem Ind Co Ltd ヒト内因子をコードするｄｎａ配列
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
JPH07503372A (ja) 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
WO1993015115A1 (en) 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. E. coli dna polymerase iii holoenzyme and subunits
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (de) 1992-06-08 1995-11-22 Univ California Auf spezifische gewebe abzielende verfahren und zusammensetzungen.
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
WO1993025685A1 (en) * 1992-06-12 1993-12-23 Massachusetts Institute Of Technology Cloning and characterization of the cell death genes ced-3 and ced-4
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
GB9216851D0 (en) 1992-08-07 1992-09-23 Univ Manitoba Dna sequences of rat probasin gene
ATE404683T1 (de) 1992-09-25 2008-08-15 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
AU5403594A (en) * 1992-10-07 1994-04-26 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Pilin variants and uses thereof
DE69333886T2 (de) 1992-11-18 2006-07-27 Arch Development Corp., Chicago Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5348358A (en) 1993-02-22 1994-09-20 Selick David A Contact lens insertion tool
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
JP3545403B2 (ja) 1993-04-22 2004-07-21 スカイファルマ インコーポレイテッド 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
JPH09501309A (ja) 1993-05-26 1997-02-10 アメリカ合衆国 アデノ関連性ウイルスレプタンパク質および細菌性タンパク質含有融合タンパク質
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
KR100356615B1 (ko) 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
EP0722493A1 (de) 1993-07-27 1996-07-24 THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY Veränderte dna-virusvektoren und ihre anwendungen
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
DE69435224D1 (de) 1993-09-15 2009-09-10 Novartis Vaccines & Diagnostic Rekombinante Alphavirus-Vektoren
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
JPH09505561A (ja) 1993-10-01 1997-06-03 アメリカ合衆国 神経系の遺伝子治療
RU2162342C2 (ru) 1993-10-25 2001-01-27 Кэнджи Инк. Рекомбинантный аденовирусный вектор и способы его применения
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
DK0729351T3 (da) 1993-11-16 2000-10-16 Skyepharma Inc Vesikler med reguleret afgivelse af aktivstoffer
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5550213A (en) * 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
JPH07241786A (ja) 1994-03-08 1995-09-19 Fanuc Ltd 産業用ロボットの制御装置
US6780406B1 (en) 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP0710118B1 (de) 1994-04-20 1998-11-25 U.S. Department Of The Army Impfstoff gegen gram-negative bakterielle infektionen
EP0763103A4 (de) 1994-04-28 1998-07-15 Univ Michigan Genverabreichender vektor aus in adenvirus verpackter plasmid-dna und eine verpackungszellinie
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
FR2720408B1 (fr) 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 de Neisseria meningitidis.
EP1548118A2 (de) 1994-06-10 2005-06-29 Genvec, Inc. Komplementäre adenovirale Vektor-Systeme und Zelllinien
FR2722210B1 (fr) 1994-07-08 1996-08-14 Rhone Poulenc Rorer Sa Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
FR2723588B1 (fr) 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour la glutathion peroxydase
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
CA2218741A1 (en) * 1995-04-21 1996-10-24 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof
EP0830455A1 (de) 1995-05-22 1998-03-25 Chiron Corporation Positionsspezifische integration von vektorkonstrukten ins eucaryotische genom durch ein chimäres integrase-protein
SK165197A3 (en) * 1995-06-07 1999-01-11 Astra Ab Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
FR2739624B1 (fr) * 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle sous-unite tbp2 de neisseria meningitidis
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
WO1997027300A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. TOXOPLASMA GONDII ANTIGEN Tg20
HUP9901039A2 (hu) 1996-02-01 1999-07-28 North American Vaccine, Inc. Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
JP2000501621A (ja) 1996-03-29 2000-02-15 アストラ・アクテイエボラグ ヘリコバクターピロリに関係した核酸及びアミノ酸配列並びにそれらのワクチン組成物
PT914144E (pt) * 1996-05-10 2001-05-31 Univ Texas Utilizacoes terapeuticas de produtos de proteinas bip contra a meningococcemia humana
US6096529A (en) * 1996-06-10 2000-08-01 National Research Council Of Canada Recombinant α-2,3-sialyltransferases and their uses
EP0818465A1 (de) 1996-07-12 1998-01-14 Institute of Molecular Biotechnology (IMB) Department of Genome Analysis Genomische Sequenz des symbiontischen Plasmids von Rhizobium sp.NGR234
FR2751000B1 (fr) * 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
US6472518B1 (en) 1996-10-24 2002-10-29 Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services Invasion associated genes from Neisseria meningitidis serogroup B
CA2274495C (en) * 1996-12-20 2009-06-02 Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
US5763589A (en) * 1997-01-09 1998-06-09 Incyte Pharmaceuticals, Inc. Human membrane protein
CA2308606A1 (en) * 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
PT1047784E (pt) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Antigénios de neisseria meningitidis
EP2261343A3 (de) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
EP1559795A3 (de) 1998-10-09 2005-11-09 Chiron Corporation Genomische Sequenzen von Neisseria und Verfahren zu ihrer Verwendung
US6214566B1 (en) * 1998-11-16 2001-04-10 The Administrators Of The Tulane Educational Fund Method for detecting anti-squalene antibodies
EP1137777B1 (de) * 1998-12-08 2011-10-05 GlaxoSmithKline Biologicals s.a. Neue verbindungen abgeleitet von neisseria meningitidis
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
DE60043499D1 (de) * 1999-03-12 2010-01-21 Glaxosmithkline Biolog Sa Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
CN1359426A (zh) 1999-04-30 2002-07-17 希龙公司 奈瑟球菌基因组序列及其用法
PT1228217E (pt) * 1999-04-30 2013-01-28 Novartis Vaccines & Diagnostic Antígenos de neisseria conservados
CA2929348A1 (en) * 1999-05-19 2000-11-30 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
ES2564463T3 (es) 1999-10-29 2016-03-22 Glaxosmithkline Biologicals S.A. Péptidos antigénicos de Neisseriales
BRPI0107679B8 (pt) * 2000-01-17 2021-05-25 Chiron Spa composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma
ES2389719T3 (es) 2000-01-25 2012-10-30 The University Of Queensland Proteínas que comprenden regiones conservadas del antígeno de superficie de Neisseria meningitidis NhhA
CN100339482C (zh) 2000-02-28 2007-09-26 启龙股份公司 奈瑟球菌蛋白质的杂交表达
ATE346925T1 (de) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2002330681C1 (en) 2001-07-26 2015-04-02 Glaxosmithkline Biologicals S.A. Vaccines comprising aluminium adjuvants and histidine
BR0211494A (pt) 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
NZ574530A (en) 2002-08-02 2010-12-24 Glaxosmithkline Biolog Sa Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB-neisseria minigitidis
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2351579B1 (de) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Poylpeptidimpfstoffe zum breiten Schutz gegen hypervirulente Meningo-kokken-Linien
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2512917A1 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
ATE552844T1 (de) 2003-01-30 2012-04-15 Novartis Ag Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
US20070253964A1 (en) 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
BR122017002991B1 (pt) 2003-10-02 2023-01-10 Novartis Vaccines And Diagnostics S.R.L. Composições imunogênicas aquosas para múltiplos sorogrupos meningocócicos
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
MX2008016280A (es) * 2006-06-29 2009-03-26 Novartis Ag Polipeptidos a partir de neisseria meningitidis.
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20100150912A1 (en) 2007-04-11 2010-06-17 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
IN2009KN04098A (de) 2007-06-04 2015-08-28 Novartis Ag
EP2886551A3 (de) 2008-02-21 2015-09-23 Novartis AG Meningokokken-FHBP-Polypeptide
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
WO2010065473A2 (en) 2008-12-01 2010-06-10 Applied Materials, Inc. Gas distribution blocker apparatus
CA2756522C (en) * 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP2613805B1 (de) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Nada und/oder nhba überexprimierende meningococcus und davon abgeleiteten aussenmembranvesikeln

Also Published As

Publication number Publication date
EP2261338A3 (de) 2012-01-04
DE69938302T2 (de) 2009-03-12
HK1090382A1 (en) 2006-12-22
DK1645631T3 (da) 2008-02-18
EP2261339B1 (de) 2017-03-22
NZ527182A (en) 2004-06-25
AU761780B2 (en) 2003-06-12
EP2261348A3 (de) 2012-01-25
CN101293920A (zh) 2008-10-29
WO1999057280A9 (en) 2002-08-29
EP2261354A3 (de) 2012-01-11
EP2261356A3 (de) 2012-01-04
JP2012191945A (ja) 2012-10-11
CA2330838C (en) 2018-12-04
JP6025674B2 (ja) 2016-11-16
EP2261350A2 (de) 2010-12-15
US20120164166A1 (en) 2012-06-28
CN101293920B (zh) 2012-07-18
EP2261340A3 (de) 2012-01-04
DE69937419T2 (de) 2008-07-24
EP1944371A3 (de) 2008-10-08
AU3967799A (en) 1999-11-23
US20120148616A1 (en) 2012-06-14
ES2294629T3 (es) 2008-04-01
EP1645631B1 (de) 2007-10-24
CA2650642A1 (en) 1999-11-11
EP2261339A2 (de) 2010-12-15
MX343752B (es) 2016-11-22
WO1999057280A2 (en) 1999-11-11
EP2261345A3 (de) 2012-01-11
EP2261342A2 (de) 2010-12-15
EP1093517B1 (de) 2008-03-05
EP2261351A3 (de) 2012-01-11
CN1373806A (zh) 2002-10-09
WO1999057280A3 (en) 2000-08-24
US20150086582A1 (en) 2015-03-26
ES2537575T3 (es) 2015-06-09
EP2261351A2 (de) 2010-12-15
MX343744B (es) 2016-11-22
NZ508366A (en) 2004-03-26
US7988979B2 (en) 2011-08-02
EP2261354A2 (de) 2010-12-15
EP2261340B1 (de) 2017-03-08
EP2261344A3 (de) 2012-01-04
EP2261353A3 (de) 2012-01-18
EP2261355A2 (de) 2010-12-15
CY1109649T1 (el) 2014-08-13
DE69937419D1 (de) 2007-12-06
JP2012191946A (ja) 2012-10-11
US7576176B1 (en) 2009-08-18
US8524251B2 (en) 2013-09-03
EP2261353A2 (de) 2010-12-15
EP2261349A2 (de) 2010-12-15
EP2261344A2 (de) 2010-12-15
EP2261341A2 (de) 2010-12-15
EP1645631A2 (de) 2006-04-12
US20120156236A1 (en) 2012-06-21
CN100379757C (zh) 2008-04-09
EP2261339A3 (de) 2012-01-11
MX339406B (es) 2016-05-25
US20090232820A1 (en) 2009-09-17
BR9910089A (pt) 2004-06-08
EP2261350A3 (de) 2012-01-04
EP1093517A2 (de) 2001-04-25
EP2261347A2 (de) 2010-12-15
EP2261345A2 (de) 2010-12-15
EP2261343A3 (de) 2012-01-18
EP1645631A3 (de) 2006-04-19
US9266929B2 (en) 2016-02-23
PT1645631E (pt) 2008-02-04
JP5102414B2 (ja) 2012-12-19
EP2261357A2 (de) 2010-12-15
ES2304065T3 (es) 2008-09-01
US9249198B2 (en) 2016-02-02
EP2261343A2 (de) 2010-12-15
US20120135024A1 (en) 2012-05-31
EP2261338A2 (de) 2010-12-15
EP2261346A2 (de) 2010-12-15
NZ532665A (en) 2005-11-25
JP2016222709A (ja) 2016-12-28
US20150079124A1 (en) 2015-03-19
JP2013252140A (ja) 2013-12-19
MXPA00010722A (es) 2004-12-03
EP2261348A2 (de) 2010-12-15
EP1944371B1 (de) 2015-03-04
US20160030545A1 (en) 2016-02-04
EP2261347A3 (de) 2012-01-11
DE69938302D1 (de) 2008-04-17
CN1210305C (zh) 2005-07-13
JP6025675B2 (ja) 2016-11-16
JP2010166916A (ja) 2010-08-05
EP2261349A3 (de) 2012-01-11
EP2261357A3 (de) 2012-01-11
ATE376591T1 (de) 2007-11-15
DK1093517T3 (da) 2008-06-23
EP1944371A2 (de) 2008-07-16
JP2013255503A (ja) 2013-12-26
EP2261342A3 (de) 2012-01-04
EP2261341A3 (de) 2012-01-04
EP2261340A2 (de) 2010-12-15
US9139621B2 (en) 2015-09-22
JP2009183306A (ja) 2009-08-20
EP2261352A3 (de) 2012-01-04
JP2017012195A (ja) 2017-01-19
CN1754885A (zh) 2006-04-05
CY1108083T1 (el) 2014-02-12
JP2004500801A (ja) 2004-01-15
NZ541361A (en) 2008-04-30
CA2330838A1 (en) 1999-11-11
EP2261352A2 (de) 2010-12-15
PT1093517E (pt) 2008-06-12
EP2261346A3 (de) 2012-01-04
PT1944371E (pt) 2015-07-13
EP2261355A3 (de) 2012-01-11
US9249196B2 (en) 2016-02-02
EP2261356A2 (de) 2010-12-15

Similar Documents

Publication Publication Date Title
ATE388230T1 (de) Neisseria meningitidis antigene und zusammenstellungen
ATE476508T1 (de) Neisseriale antigene
BR9906927A (pt) Proteìnas de neisseria meningitidis
MXPA01003557A (es) Secuencias genomicas de neisseria y metodos para su uso.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1093517

Country of ref document: EP

EEIH Change in the person of patent owner